• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Sonnet BioTherapeutics Holdings Inc.

    7/25/25 4:15:26 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SONN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Sonnet BioTherapeutics Holdings, Inc.

    (Name of Issuer)


    COM NEW

    (Title of Class of Securities)


    83548R204

    (CUSIP Number)


    07/14/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    83548R204


    1Names of Reporting Persons

    Republic Digital Opportunistic Digital Assets Master Fund, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    260,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    260,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    260,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.2 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Calculations of the percentage set forth in Row 11 are based on the quotient obtained by dividing (a) the number of shares of Sonnet BioTherapeutics Holdings, Inc. Common Stock beneficially owned by the Reporting Persons as set forth in Row 9 by (b) the 6,264,165 shares of Common Stock outstanding as of July 18, 2025, as reported in the Issuer's current report on Form 8-K, as filed with the U.S. Securities and Exchange Commission on July 18, 2025.


    SCHEDULE 13G

    CUSIP No.
    83548R204


    1Names of Reporting Persons

    Joseph Naggar
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    260,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    260,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    260,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.2 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Calculations of the percentage set forth in Row 11 are based on the quotient obtained by dividing (a) the number of shares of Sonnet BioTherapeutics Holdings, Inc. Common Stock beneficially owned by the Reporting Persons as set forth in Row 9 by (b) the 6,264,165 shares of Common Stock outstanding as of July 18, 2025, as reported in the Issuer's current report on Form 8-K, as filed with the U.S. Securities and Exchange Commission on July 18, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Sonnet BioTherapeutics Holdings, Inc.
    (b)Address of issuer's principal executive offices:

    100 Overlook Center, Suite 102, Princeton, New Jersey, 08540
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is being filed jointly by Republic Digital Opportunistic Digital Assets Master Fund, Ltd. ("Republic"), and Joseph Naggar ("Naggar"), who is the Chief Executive Officer and Chief Investment Officer of Republic Digital Fund Manager LLC, the Investment Manager of Republic. Republic and Mr. Naggar are hereinafter sometimes collectively referred to as the "Reporting Persons." Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
    (b)Address or principal business office or, if none, residence:

    The principal business address of the Reporting Persons is 149 5th Avenue, 10th Floor, New York, NY 10010.
    (c)Citizenship:

    Republic is organized as a limited company under the laws of Cayman Islands. Mr. Naggar is a citizen of the United States of America.
    (d)Title of class of securities:

    COM NEW
    (e)CUSIP No.:

    83548R204
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    (i) Republic - 260,000 shares of Common Stock (ii) Naggar - 260,000 shares of Common Stock
    (b)Percent of class:

    (i) Republic - 4.15% (ii) Naggar - 4.15% The percentages set forth herein are based on 6,264,165 shares of Common Stock outstanding as of July 18, 2025,as reported in the Issuer's current report on Form 8-K, as filed with the U.S. Securities and Exchange Commission on July 18, 2025. As of July 14, 2025, the Reporting Persons' beneficial ownership of the Issuer's Common Shares exceeded 5% of the 3,332,728 shares of Common Stock then-outstanding, thereby requiring the Reporting Persons to file this Schedule 13G pursuant to Rule 13d-1(c) under the Act. However, as of July 18, 2025, the Reporting Persons' beneficial ownership had fallen below 5%, upon closing of a private placement offering and certain of the Issuer's outstanding warrants being exercised, and the number of shares of Common Stock outstanding increased by 2,931,437 shares of Common Stock to 6,264,165 shares of Common Stock outstanding. Accordingly, as of the date of filing of this Schedule 13G, none of the Reporting Persons' beneficial ownership remains above 5% of the shares of Common Stock outstanding.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    (i) Republic - 0 (ii) Naggar - 0

     (ii) Shared power to vote or to direct the vote:

    (i) Republic - 260,000 (ii) Naggar - 260,000

     (iii) Sole power to dispose or to direct the disposition of:

    (i) Republic - 0 (ii) Naggar - 0

     (iv) Shared power to dispose or to direct the disposition of:

    (i) Republic - 260,000 (ii) Naggar - 260,000

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Republic Digital Opportunistic Digital Assets Master Fund, Ltd.
     
    Signature:/s/ Joseph Naggar
    Name/Title:Joseph Naggar, Authorized Signatory
    Date:07/25/2025
     
    Joseph Naggar
     
    Signature:/s/ Joseph Naggar
    Name/Title:Joseph Naggar
    Date:07/25/2025
    Exhibit Information

    Exhibit 99.1 - Joint Filing Agreement, dated July 25, 2025, by and between Republic Digital Opportunistic Digital Assets Master Fund, Ltd. and Joseph Naggar.

    Get the next $SONN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SONN

    DatePrice TargetRatingAnalyst
    2/9/2022$5.00 → $2.00Buy
    BTIG
    12/20/2021$8.00 → $2.50Buy
    Chardan Capital
    12/16/2021$2.00Buy
    HC Wainwright & Co.
    9/15/2021$5.00Buy
    BTIG
    More analyst ratings

    $SONN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Medical Officer Kenney Richard T

    4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)

    8/21/25 4:48:43 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Kenney Richard T was granted 8,000 shares, increasing direct ownership by 582% to 9,374 units (SEC Form 4)

    4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)

    7/15/25 7:35:19 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bhatt Nailesh was granted 10,000 shares, increasing direct ownership by 1,828% to 10,547 units (SEC Form 4)

    4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)

    7/15/25 7:35:19 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SONN
    SEC Filings

    View All

    SEC Form DEF 14A filed by Sonnet BioTherapeutics Holdings Inc.

    DEF 14A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Filer)

    8/26/25 5:01:29 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Sonnet BioTherapeutics Holdings Inc.

    10-Q - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Filer)

    8/13/25 4:06:40 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sonnet BioTherapeutics Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Filer)

    8/1/25 4:58:26 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SONN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $SONN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $SONN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sonnet Releases Virtual Investor "What This Means" Segment

    - Dr. Richard Kenney, Chief Medical Officer of Sonnet, discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221) - Watch the "What This Means" video here PRINCETON, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced the release of a Virtual Investor "What This Means" segment.As part of the segment, Dr. Richard Kenney, Chief Medical Officer, discussed its recent update on its SB221 clinical trial including that a) enrollment of

    8/11/25 9:15:00 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

    Sonnet's lead product, SON-1010 (IL12-FHAB), is being evaluated in combination with atezolizumab (Tecentriq®) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221) Topline safety, cytokine, and efficacy data suggest a strong potential for clinical benefit using the current maximum dose of SON-1010 A second patient with PROC in the E6 combination cohort recently had a confirmed PR, so 2 out of 3 total patients had a tumor response at that dose After completing enrollment of the expansion group at that top dose, a new E7 cohort has been added to examine the safety and effectiveness of a 25% higher maintenance dose of SON-1010 PRINCETON, N.J., Aug. 04, 2025 (GLOBE NEW

    8/4/25 8:40:00 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy

    PRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics, Inc., (NASDAQ:SONN) ("Sonnet" or the "Company") today announced that it has entered into a definitive agreement (the "Business Combination Agreement", or the "BCA") for a business combination (the "Business Combination") with Rorschach I LLC ("Rorschach"), a newly-formed entity formed by an entity affiliated with Atlas Merchant Capital LLC ("Atlas"), an affiliate of Paradigm Operations LP ("Paradigm"), and additional sponsors (all together, the "Sponsors"), to transform its business by building a reserve of HYPE, the token of the Hyperliquid Layer-1 blockchain. At the closing of the Business Combination, the newly-

    7/14/25 6:00:00 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mohan Pankaj bought 34,375 shares, increasing direct ownership by 137% to 59,526 units (SEC Form 4)

    4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)

    10/27/23 8:00:08 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rao Raghu bought 15,625 shares, increasing direct ownership by 1,315% to 16,813 units (SEC Form 4)

    4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)

    10/27/23 8:00:10 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG reiterated coverage on Sonnet BioTherapeutics with a new price target

    BTIG reiterated coverage of Sonnet BioTherapeutics with a rating of Buy and set a new price target of $2.00 from $5.00 previously

    2/9/22 6:54:44 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital reiterated coverage on Sonnet BioTherapeutics with a new price target

    Chardan Capital reiterated coverage of Sonnet BioTherapeutics with a rating of Buy and set a new price target of $2.50 from $8.00 previously

    12/20/21 8:31:50 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on Sonnet BioTherapeutics with a new price target

    HC Wainwright & Co. initiated coverage of Sonnet BioTherapeutics with a rating of Buy and set a new price target of $2.00

    12/16/21 8:15:32 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SONN
    Leadership Updates

    Live Leadership Updates

    View All

    Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

    PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced with deep and profound sadness the tragic passing of Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer. The Company's Board of Directors has unanimously approved the appointment of current board member Raghu Rao, as Interim Chief Executive Officer of the Company, and the promotion of Stephen McAndrew, Ph.D., the Company's current Chief Business Officer, to President and Chief Business Officer of the Company. The Board intends

    4/1/25 7:30:00 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

    PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today the appointment of Stephen J. McAndrew, Ph.D., as Chief Business Officer, effective February 17, 2025. Dr. McAndrew brings more than 30 years of experience with various business models and types of transactional agreements involving biologics at different stages of development. During the course of his tenure at Sonnet, Dr. McAndrew has served as Vice President and then Senior Vice President, Business Development, and has been responsible for developing and leading the Compa

    2/13/25 8:30:00 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sonnet BioTherapeutics Appoints Ms. Lori McNeill to the Board of Directors and Formalizes the Company's Business Advisory Committee

    Ms. McNeill is a former executive of Pfizer and an entrepreneur with expertise in marketing and public relations; she will sit on the Board of Directors and serve as the Chairperson of Sonnet's newly formed Business Advisory Committee (BAC)The BAC will advise the company on business collaborations, communications and interactions with the Federal GovernmentPRINCETON, NJ / ACCESSWIRE / September 26, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that Lori McNeill has been appointed to the Company's Board of Directors. Ms. McNeill's Board position will also round out the composition of the compan

    9/26/22 8:00:00 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SONN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Sonnet BioTherapeutics Holdings Inc. (Amendment)

    SC 13G/A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Subject)

    1/2/24 4:19:28 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Sonnet BioTherapeutics Holdings Inc. (Amendment)

    SC 13G/A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Subject)

    11/17/23 11:32:52 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Sonnet BioTherapeutics Holdings Inc. (Amendment)

    SC 13G/A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Subject)

    11/6/23 11:35:23 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care